Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 274 Cr.
- Current Price ₹ 185
- High / Low ₹ 326 / 182
- Stock P/E 37.7
- Book Value ₹ 49.8
- Dividend Yield 0.54 %
- ROCE 13.5 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 19.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
95.27 | 95.15 | 78.47 | 75.22 | |
74.56 | 73.69 | 65.10 | 63.80 | |
Operating Profit | 20.71 | 21.46 | 13.37 | 11.42 |
OPM % | 21.74% | 22.55% | 17.04% | 15.18% |
1.00 | 1.05 | 1.18 | 1.56 | |
Interest | 0.17 | 0.82 | 0.83 | 0.76 |
Depreciation | 1.59 | 2.04 | 2.29 | 2.42 |
Profit before tax | 19.95 | 19.65 | 11.43 | 9.80 |
Tax % | 25.51% | 26.92% | 26.16% | |
14.86 | 14.36 | 8.44 | 7.26 | |
EPS in Rs | 10.03 | 9.70 | 5.70 | 4.91 |
Dividend Payout % | 19.93% | 20.63% | 17.55% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -41% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 42% |
3 Years: | 14% |
1 Year: | -34% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 14.81 | 14.81 | 14.81 | 14.81 |
Reserves | 39.87 | 51.60 | 57.45 | 58.95 |
9.75 | 14.43 | 26.46 | 28.71 | |
19.34 | 12.38 | 11.15 | 13.98 | |
Total Liabilities | 83.77 | 93.22 | 109.87 | 116.45 |
25.49 | 33.11 | 33.09 | 56.58 | |
CWIP | 0.00 | 0.31 | 21.06 | 1.97 |
Investments | 7.08 | 16.79 | 19.83 | 20.58 |
51.20 | 43.01 | 35.89 | 37.32 | |
Total Assets | 83.77 | 93.22 | 109.87 | 116.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
9.16 | 14.82 | 16.54 | |
-2.64 | -20.48 | -25.85 | |
3.96 | 0.96 | 7.40 | |
Net Cash Flow | 10.49 | -4.70 | -1.91 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 72.33 | 51.56 | 71.17 |
Inventory Days | 92.33 | 124.92 | 99.63 |
Days Payable | 92.57 | 71.19 | 83.28 |
Cash Conversion Cycle | 72.09 | 105.28 | 87.52 |
Working Capital Days | 68.46 | 79.83 | 76.94 |
ROCE % | 27.63% | 13.46% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1d
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Newspaper Publication of Unaudited Financial Results for the Quarter and Half Year ended 30th September 2024
-
Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024
11 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th November 2024
11 Nov - Approved unaudited financial results for Q2 FY 2024-25.
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries